India Glycols’ apparent 80% share-price drop reflects demerger, not a sell-off
India Glycols began trading ex-demerger on September 2, with its spirits business moving to IGL Spirits and bio-pharma unit to Ennature Bio Pharma. Shareholders receive one IGL Spirits share for each India Glycols share and one Ennature share for every three India Glycols shares; both entities plan NSE and BSE listings.
What happened
India Glycols traded ex-demerger, causing an apparent nearly 80% share-price fall. Its chemicals business remains in India Glycols, while spirits and bio-pharma
Key facts
- Shares opened at Rs 225, down 79.76% from previous close of Rs 1,111.70
- Share entitlement: 1 IGL Spirits share for every 1 India Glycols share
- Share entitlement: 1 Ennature Bio Pharma share for every 3 India Glycols shares
- Record date: September 2, 2026
- Market capitalization: approximately Rs 1,540-1,550 crore
- India Glycols June 2026 quarterly net revenue: Rs 345 crore
- IGL Spirits June 2026 quarterly revenue: Rs 694 crore
- Ennature Bio Pharma June 2026 quarterly revenue: Rs 90 crore
- Stock gained over 35% in one year and nearly 235% in five years
Why this matters
The separation creates distinct listed alco-bev and bio-pharma vehicles, potentially sharpening strategic partnerships, capital allocation and valuation comparables once IGL Spirits and Ennature begin trading.
What to watch
- NSE and BSE trading commencement dates and opening-price discovery for IGL Spirits and Ennature Bio Pharma.
- Post-listing liquidity, delivery volumes and any sharp divergence between theoretical and traded values.
- Management commentary on debt allocation, intercompany arrangements, dividend policy and capital expenditure.
- Standalone quarterly results showing spirits margins, volume growth and state excise/regulatory impacts.
- Index, mutual-fund or ETF rebalancing and institutional ownership changes following the corporate action.
- Any clarification from exchanges or trading platforms on adjusted historical prices and the apparent 80% decline.
- Track record dates, share-credit timelines and exchange listing approvals for IGL Spirits and Ennature Bio Pharma.
- Compare the implied combined market capitalisation after listing with India Glycols' pre-demerger valuation rather than using the parent share-price change alone.
- Watch for standalone revenue, EBITDA, debt, working-capital and capex disclosures for all three entities.
- Expect brokerages and data vendors to reset historical charts, target prices and financial estimates after the listed-entity financials become available.
- Monitor whether IGL Spirits outlines expansion in premium brands, state-market distribution, capacity and route-to-market partnerships.